Mabion is a fully integrated CDMO located in central Europe and established in 2007 to develop and support the development of protein-based biotherapeutics, including monoclonal antibodies, vaccine antigens and other large proteins. With 17 years of experience, Mabion offers an “end-to-end” solution, covering all stages of biologic drug development: from early clone selection and small-scale manufacturing through process scale-up, large-scale manufacturing and quality control down to sterile fill-finish, packaging and serialization, bioanalytics and regulatory support. A combination of broad capabilities and well-qualified, experienced staff makes Mabion a perfect long-term partner for any project involving therapeutic proteins, whether your product is in pre-clinical or clinical development or already commercially available. In addition to long-term partnerships, Mabion can also provide tailored services depending on your needs.